Treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy are under review.

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

Genmab's (GMAB) stock gains as its lymphoma drug epcoritamab developed with AbbVie (ABBV) succeeds in a Phase 3 lymphoma ...

An oral GLP-1 induced up to 12.4% weight loss at 72 weeks for adults with overweight or obesity, according to topline results ...

TRON (TRX) has been making waves lately, with its price climbing to $0.33, largely driven by the momentum of stablecoins ...

FC Cincinnati closes Phase One of Leagues Cup play Thursday night against Chivas Guadalajara. Here's what needs to happen for ...

It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting ...

While the Stage III lawn watering ban is no longer in effect, customers are asked to voluntarily reduce watering by 25%.

Officials with the Coachella Valley Rail project say they're on track despite federal cuts to California's separate high-speed rail line.

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

GAAP net loss increased to $26.7 million in Q2 2025, driven by higher research and development spending and public company costs. The RAP-219 Phase 2a epilepsy trial is fully enrolled and remains on ...

Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo ...